Posted by Michael Wonder on 19 Oct 2023
BrainStorm Cell Therapeutics to meet with US FDA to discuss development plan for NurOwn as a treatment of ALS
18 October 2023 - Biologics license application to be withdrawn without prejudice.
BrainStorm Cell Therapeutics today announced that the US FDA has invited the Company to request an expedited face to face meeting to discuss the path forward for NurOwn as a treatment for amyotrophic lateral sclerosis.
